The study, led by Tomader Ali of Imperial College Abu Dhabi and Ayman Al Hayek of the Saudi Arabian Ministry of Defense Health Services and Prince Sultan Military Medical City, surveyed 82 diabetes educators between June and July 2025. The questionnaire, adapted from a validated Delphi-derived tool, contained 23 questions covering knowledge and confidence, training challenges, success factors, educational needs, and professional development pathways. Every one of the 82 invited participants completed the survey, yielding a 100 percent response rate—a remarkable achievement in survey research that strengthens the reliability of the results. Responses were captured through Likert scales, multiple-choice items, and free-text fields, with quantitative data analyzed descriptively.

The MiniMed™ 780G represents a significant leap in type 1 diabetes management technology. It is an advanced hybrid closed-loop system that combines a continuous glucose monitor, an insulin pump, and sophisticated algorithms capable of automatically adjusting basal insulin delivery and administering autocorrections every five minutes. Its SmartGuard™ technology is designed to keep blood glucose within a tight target range with minimal user intervention. The system has accumulated substantial real-world evidence, with data from more than 100,000 users across Europe, the Middle East, and Africa collected over three years demonstrating meaningful improvements in time spent within the target glucose range. A landmark analysis published in Diabetes Care found that real-world users of the system achieved a high proportion of time in what researchers call the “tight range”—a glucose band even narrower than the standard target range of 70 to 180 mg/dL.

Yet the technology’s sophistication creates a paradox for clinical practice. The very algorithms that make the 780G effective also make it conceptually demanding for patients to understand and for educators to teach. This is where the new survey delivers its most actionable insights. When asked about their confidence across key topics related to the MiniMed™ 780G, most diabetes educators reported high confidence in the system’s core functions—managing basal insulin adjustment, understanding sensor integration, and navigating basic device operations. But one domain stood out as a consistent weak point: managing high-fat and high-protein meals. Only 56.1 percent of educators expressed confidence in this area, making dietary management of complex meals the most significant knowledge gap identified by the study.

This finding has deep physiological and technical significance. High-fat, high-protein meals delay gastric emptying and slow glucose absorption, creating a mismatch between the timing of insulin delivery and the appearance of glucose in the bloodstream. The MiniMed™ 780G addresses this partially through its meal detection and autocorrection capabilities, but optimal outcomes still depend heavily on how patients are taught to program meal boluses, extend delivery, and interpret postprandial sensor trends. If nearly half of the educators responsible for patient training lack confidence in this domain, the implication is that a substantial proportion of patients may be receiving incomplete or inconsistent guidance on one of the most challenging aspects of daily diabetes self-management with automated insulin delivery.

The survey also probed the specific barriers educators face during patient onboarding. Managing patient expectations emerged as the single most common challenge, cited by 33.6 percent of respondents. This is hardly surprising to anyone familiar with the marketing-versus-reality tension in diabetes technology. Patients and families often arrive with the expectation that a hybrid closed-loop system will function like an artificial pancreas—fully automated and requiring no thought from the user. In reality, the 780G still requires accurate carbohydrate counting, attention to sensor placement and calibration, and an understanding of how exercise, illness, stress, and hormonal fluctuations affect glucose dynamics. Setting realistic expectations while preserving patient enthusiasm is a delicate communication task that many educators feel unprepared to perform.

The second most cited challenge, at 20.4 percent, was explaining SmartGuard™ technology itself. The algorithm behind SmartGuard™ involves automated basal correction, automated insulin microboluses delivered every five minutes, and adjustable glucose targets as low as 100 mg/dL, all governed by predictive models that anticipate where glucose is heading rather than merely reacting to current readings. Translating this algorithmic sophistication into language that a newly diagnosed teenager—or an elderly patient newly transitioning from multiple daily injections—can genuinely grasp is a pedagogical challenge that the survey data suggest remains unresolved for many educators. Additional barriers included the lack of structured educational materials (17.1 percent), troubleshooting device alarms (12.5 percent), and teaching device settings (11.8 percent).

The study also identified what educators say would most strengthen their professional capability in this field. Mentorship was the leading driver of professional development, cited by 24.9 percent of respondents, followed closely by strong educator networks at 21.0 percent. When asked about priorities for accreditation and credentialing, educators pointed to international certification bodies (25.6 percent) and continuing education programs (20.3 percent) as the most important mechanisms for standardizing training quality. These findings suggest that the path forward is not simply more training volume, but better-connected, better-structured, and internationally harmonized training infrastructure that allows educators to learn from one another across borders and health systems.

The regional scope of the survey adds particular value. Type 1 diabetes care in the Middle East, Africa, and parts of Eastern Europe and Central Asia faces distinctive challenges that differ substantially from those in Western Europe or North America. In the Arabian Peninsula, dietary patterns rich in rice, dates, and fatty meats create specific postprandial glucose challenges, and cultural practices such as Ramadan fasting impose dramatic shifts in daily routine that demand sophisticated system management. Prior research has shown that the MiniMed™ 780G adapts remarkably well to the routine disruptions of Ramadan, but only when patients have been properly educated on how the system responds to fasting and refeeding. In Central and Eastern Europe, the challenge is often one of resource allocation and inconsistent access to structured diabetes education programs. In parts of Africa, the burden of undiagnosed and inadequately managed type 1 diabetes remains enormous, and the shortage of trained diabetes technology educators represents a critical bottleneck to expanding access to advanced therapy.

The study’s authors conclude that specialist healthcare professionals are indeed competent in the use of advanced diabetes technologies, but they emphasize that standardized, personalized, and patient-centered educational programs are essential to fully realize the potential of these systems. The Delphi consensus published in Acta Diabetologica in 2024, which formed the methodological foundation for this survey, had already outlined an optimal educational pathway for diabetes educators training patients on the MiniMed™ 780G. The new survey now provides empirical evidence about where current practice falls short of that ideal, giving health systems, professional societies, and industry partners a concrete roadmap for improvement.

What emerges from this research is a call to action that resonates far beyond the specific device or regions studied. As automated insulin delivery systems become the standard of care for type 1 diabetes worldwide, the humans who teach patients to use them are the critical link between technological promise and clinical reality. Investment in structured curricula, mentorship programs, international certification, and regionally adapted educational materials is not a luxury—it is the necessary infrastructure for ensuring that the remarkable engineering embedded in devices like the MiniMed™ 780G translates into the time-in-range improvements, reduced hypoglycemia, and quality-of-life gains that patients deserve. The 82 educators who participated in this survey have, in effect, mapped the terrain for that investment.